Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathryn Rankin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer|February 11, 2004
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139Mark M Zalupski, Cathryn Rankin, James R Ryan, et al.
Investigational New Drugs|October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Cancer|July 22, 2014
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)Cornelia M Ulrich, Cathryn Rankin, Adetunji T Toriola, et al.
International Journal of Clinical Oncology|November 20, 2014
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001Deborah T Blumenthal, Cathryn Rankin, Keith J Stelzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group StudyLinda L Garland, Cathryn Rankin, David R Gandara, et al.
Cancer|June 4, 2008
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trialDeborah T Blumenthal, Cathryn Rankin, Harmon J Eyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005Yongli Ji, Cathryn Rankin, Steven Grunberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer|February 11, 2004
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139Mark M Zalupski, Cathryn Rankin, James R Ryan, et al.
Investigational New Drugs|October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Cancer|July 22, 2014
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)Cornelia M Ulrich, Cathryn Rankin, Adetunji T Toriola, et al.
International Journal of Clinical Oncology|November 20, 2014
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001Deborah T Blumenthal, Cathryn Rankin, Keith J Stelzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group StudyLinda L Garland, Cathryn Rankin, David R Gandara, et al.
Cancer|June 4, 2008
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trialDeborah T Blumenthal, Cathryn Rankin, Harmon J Eyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005Yongli Ji, Cathryn Rankin, Steven Grunberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Pageof 2